Science and Technology in Medicine
Explore this Section
Prof A Murray Brunt
|Title:||Consultant Clinical Oncologist|
|Phone:||+44 (0)1782 672565 (sec)|
|Location:||Staffordshire Oncology Centre, University Hospitals of North Midlands, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent, ST4 6QG, United Kingdom
|Role:||ISTM Research theme: Therapeutics
|Contacting me:||By e-mail please.|
Prof Murray Brunt is Chief investigator on the FAST-Forward £3.6m NIHR-HTA funded trial and two others and active on 8 national/international breast cancer trial management groups. For the majority of trials in which he has been involved, Prof Brunt has been the principal investigator for North Staffordshire and involved in all local aspects from the initiation, set up, recruitment through to follow up until trial closure.
Prof Brunt initiated the first weekly clinical trial follow up clinic in the Guy Hilton Research Centre, which has been running since 2007. He been a major collaborator on a total of over 60 national or international studies and has just been appointed the first NIHR-Cancer Research lead for the West Midlands in the new national research set-up.
ISTM Research theme: Therapeutics
Prof Brunt’s research is in breast cancer, haematological malignancies (predominantly lymphomas), and skin cancer. It is conducted primarily through breast cancer clinical trials, on three levels:
- trial development, management, and publication of results.
- a principal investigator and recruiter to trials
- the practical application of clinical trials and patient interaction.
The areas of breast cancer trials in which Prof Brunt is involved directly relate to his practice as a clinical oncologist:
- hormone therapy,
- targeted biological therapy
Full Publications List show
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. LANCET ONCOLOGY, vol. 14(10), 989-998. link> doi>2013.
A 5-fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the randomised UK FAST trial (ISRCTN62488883, CRUKE/04/015). EJC SUPPLEMENTS (vol. 7, p. 2). link>2009.
Prospective randomised trial testing 5.7GY and 6.0GY fractions of whole breast radiotherapy in women with early breast cancer ('fast' trial). BRITISH JOURNAL OF CANCER (vol. 91, p. S80). link>2004.
Hyperfractionated accelerated radiotherapy for carcinoma of the oesophagus. 5 years follow-up. EUROPEAN JOURNAL OF CANCER (vol. 33, p. 468). link>1997.
- Medical Defence Union
- Royal College of Radiologists
- Royal College of Physicians, London
- British Oncology Association
- Radiotherapists Visiting Society
- Hospital Consultant & Specialists Association
- North Staffordshire Medical Institute
- National deputy lead for the Breast Site Orientated electronic Network (SOeN): 2006-present.
- Member of National Collaborating Centre for Cancer (NCCC) advanced breast cancer guideline development group: 2006-9 (the lifetime of the project).
- Member of West Midlands Cancer Intelligence Unit steering committee: 2005-present.
- Member of Regional peer review team from 1997, clinical team leader from 2005-present.
Chair of R & D steering committee: 2007 to present.
- Deputy Lead of NCRN R & D for North West Midlands Cancer Network 2004-6 (until networks amalgamated).